FAM
TPST icon

Fred Alger Management’s Tempest Therapeutics TPST Stock Holding History

Fred Alger Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2
Closed -$217K – 538
2015
Q1 		$217K Buy
+2
New +$266K ﹤0.01% 614

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fred Alger Management's TPST Position: Q2 2015 in Review

Fred Alger Management sold out of Tempest Therapeutics (TPST) in Q2 2015, closing a stake of 2 shares — an estimated $217K sold.

Fred Alger Management first reported a position in TPST in Q1 2015 and held it in 1 quarter. The position peaked at $217K in Q1 2015. 92 funds tracked by Wall St. Rank hold TPST as of Q2 2015.

  • Fred Alger Management reported no remaining Tempest Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Fred Alger Management sold 2 Tempest Therapeutics shares in Q2 2015, an estimated $217K.
  • Fred Alger Management first reported a position in Tempest Therapeutics in Q1 2015 and held it in 1 quarter.
  • Fred Alger Management's Tempest Therapeutics position peaked at $217K in Q1 2015.
  • 92 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2015.

Based on Fred Alger Management's 13F filing for Q2 2015, filed 14 Aug 2015.